

LABELLING

PARTICULARS TO APPEAR ON THE OUTER AND IMMEDIATE PACKAGING BOTTLE

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine/Nevirapine/Zidovudine 150 mg/200 mg/300 mg Tablets *

2. STATEMENT OF ACTIVE SUBSTANCE

Each tablet contains lamivudine 150 mg, nevirapine 200 mg and zidovudine 300 mg

3. LIST OF EXCIPIENTS

Contains lactose.
See the patient information leaflet for further information

4. PHARMACEUTICAL FORM AND CONTENTS

60 film-coated tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Oral use
Read the patient information leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP {MM/YYYY}

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's (NMRA) responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C. Store in the original container. Protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE SUPPLIER

Shanghai Desano Bio-pharmaceutical Co., Ltd.
1479 Zhangheng Road
China (Shanghai) Pilot Free Trade Zone
Shanghai 201203
China

12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)

HA684

13. MANUFACTURER'S BATCH NUMBER

<Batch> {number}

14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE